Sarepta Therapeutics Inc. (CH:AB3A)
NASDAQ:AB3A
AB3A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Improved Leverage And Rebuilt EquityBalance-sheet repair is durable: debt has stayed near $1B while equity has rebuilt, cutting debt-to-equity below 1x. That materially improves financial flexibility for R&D funding and M&A optionality over the next 2–6 months versus earlier high-leverage periods.
TTM Profitability And Positive Cash-flow InflectionA sustained inflection to positive operating and free cash flow (TTM) signals the company can fund core operations and select programs from internal cash. This reduces dilution risk and supports multi-quarter pipeline execution and commercialization investments.
High Product Gross Margins And Falling Cost Of SalesVery high unit gross margins (82%) and lower cost of sales point to structurally attractive economics for product sales. Durable margin strength provides room to invest in sales expansion, maintain R&D, and absorb lumpier one-time therapy timing without immediate margin erosion.
Bears Say
Revenue Decline And Demand Recovery LagA sharp revenue decline and measured demand recovery for Alevitus imply persistent commercial headwinds. Slow patient decision cycles and enrollment-to-infusion timelines mean sales recovery may take several quarters, making revenue visibility and cash conversion uncertain.
Revenue Distortion From Non-cash Collaboration ItemsLarge non-cash collaboration recognition materially inflates reported revenue and obscures product-sales momentum and recurring cash generation. Reliance on lumpy, non-cash items undermines the durability of reported top-line growth and complicates forecasting over multiple quarters.
Clinical/regulatory Uncertainty For Non-ambulatory Alevitus UseRegulatory reliance on a small, open-label cohort to address liver safety in non-ambulatory patients creates structural execution risk. If results are inconclusive, regulators may require larger studies, delaying label expansion and constraining longer-term addressable market growth.
Sarepta Therapeutics News
AB3A FAQ
What was Sarepta Therapeutics Inc.’s price range in the past 12 months?
Currently, no data Available
What is Sarepta Therapeutics Inc.’s market cap?
Sarepta Therapeutics Inc.’s market cap is CHF1.44B.
When is Sarepta Therapeutics Inc.’s upcoming earnings report date?
Sarepta Therapeutics Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 38 days.
How were Sarepta Therapeutics Inc.’s earnings last quarter?
Sarepta Therapeutics Inc. released its earnings results on May 06, 2026. The company reported $2.256 earnings per share for the quarter, beating the consensus estimate of $0.765 by $1.492.
Is Sarepta Therapeutics Inc. overvalued?
According to Wall Street analysts Sarepta Therapeutics Inc.’s price is currently Undervalued.
Does Sarepta Therapeutics Inc. pay dividends?
Sarepta Therapeutics Inc. does not currently pay dividends.
What is Sarepta Therapeutics Inc.’s EPS estimate?
Sarepta Therapeutics Inc.’s EPS estimate is 0.16.
How many shares outstanding does Sarepta Therapeutics Inc. have?
Currently, no data Available
What happened to Sarepta Therapeutics Inc.’s price movement after its last earnings report?
Sarepta Therapeutics Inc. reported an EPS of $2.256 in its last earnings report, beating expectations of $0.765. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Sarepta Therapeutics Inc.?
Currently, no hedge funds are holding shares in CH:AB3A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sarepta Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
CHF18.59 (― Downside)
CHF18.59 (― Downside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.24%
12-Months-Change
Fundamentals
Return on Equity
4.89%
Trailing 12-Months
Asset Growth
-8.27%
Trailing 12-Months
Company Description
Sarepta Therapeutics Inc.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
AB3A Company Deck
AB3A Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely constructive tone: Sarepta reported profitable Q1 results, strong gross margins, and a $748M cash balance while reiterating full-year guidance of $1.2B–$1.4B. The company highlighted meaningful clinical progress—notably robust early siRNA data (FSHD, DM1), encouraging EMBARK 3‑year and MRI evidence for Alevitus, regulatory progress with sNDA submissions, and commercialization initiatives (expanded sales force). Offsetting these positives were lower Alevitus product sales driving a modest YoY revenue decline (–2%), an information gap slowing demand recovery, short-term cash outflows tied to planned Arrowhead payments, and unresolved safety/regulatory uncertainty for non‑ambulatory Alevitus use that depends on small open‑label cohorts. Overall, the call emphasized stabilization and long‑term opportunity but signaled that commercial recovery for Alevitus will be gradual and that some clinical/regulatory risks remain.View all CH:AB3A earnings summariesAB3A Stock 12 Month Forecast
Average Price Target
$18.59
BioCryst
―
Mesoblast
―
Cogent Biosciences
―
Arcutis Biotherapeutics
―
Dyne Therapeutics
―
Options Prices
Currently, No data available
---